Celecoxib
Chronic Prostatitis
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Xintian Pharmaceutical
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06159114CT.gov Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Prostatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Xintian Pharmaceutical | Approved | BB · 64 |
| Ningmitai | Xintian Pharmaceutical | P4 | BBB |
| Serenoa Repens Extract | Clinica Urologica Molinette - Città della Saliute e della Scienza | P4 | BB |
| Selenium | Clinica Urologica Molinette - Città della Saliute e della Scienza | P4 | BB |
| Tamsulosin | Xintian Pharmaceutical | P4 | BB |
| Palmitic Monoethanolamide | Clinica Urologica Molinette - Città della Saliute e della Scienza | P4 | BB |
| om-89 [uro-vaxom® ] | AJU Pharm Co., Ltd. | P4 | BB |
| Cernilton | University of Giessen | P3 | BB |
| Pregabalin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | B |
+11 more in the Chronic Prostatitis cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Celecoxib in Chronic Prostatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/celecoxib-chronic-prostatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →